RxDoctor Payments Data

Sunil Prakash Chand, MD

Cardiovascular Disease · Wilson, NCNPI 1558558999

Payments from drug & device makers

$231,918in general payments, 2019–2025

Across 663 payments — averaging $349.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$103K
  • Boston Scientific$56K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$42K
  • Lilly USA, LLC$22K
  • Abbott$5K
  • Johnson & Johnson$960
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$9,4364%
  • Speaking & faculty fees$196,30885%
  • Travel & lodging$9,4844%
  • Food & beverage$16,6337%
  • Education$580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$231,918 in reported general payments places this provider in the 90th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$361,894
Medicare patients
968
Services billed
9,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban684$656,145
EntrestoSacubitril/Valsartan201$170,957
XareltoRivaroxaban173$151,095
JardianceEmpagliflozin71$65,869
Repatha SureclickEvolocumab41$44,724
BrilintaTicagrelor26$24,564
MultaqDronedarone Hcl14$19,940
Praluent PenAlirocumab11$14,807
Ranolazine ErRanolazine57$8,243
FarxigaDapagliflozin Propanediol11$6,069
Metoprolol Succinate503$5,327
Bumetanide229$4,823
Flecainide Acetate193$4,361
Digoxin160$3,187
Dofetilide21$2,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$155$656,145684 claims
NovartisEntresto$634$170,957201 claims
Johnson & JohnsonXarelto$960$151,095173 claims
Boehringer IngelheimJardiance$103,141$65,86971 claims
AstraZenecaBrilinta, Farxiga$341$30,63337 claims
Sanofi-aventis U.S. LLCMultaq$24$19,94014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Wilson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →